Pharsight

Drugs that contain Brimonidine Tartrate

1. Alphagan P patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5424078

(Pediatric)

ABBVIE Aqueous ophthalmic formulations and methods for preserving same
Dec, 2012

(11 years ago)

US9295641 ABBVIE Compositions containing alpha-2-adrenergic agonist components
Jul, 2021

(2 years ago)

US6562873 ABBVIE Compositions containing therapeutically active components having enhanced solubility
Jul, 2021

(2 years ago)

US9687443 ABBVIE Compositions containing alpha-2-adrenergic agonist components
Jul, 2021

(2 years ago)

US10307368 ABBVIE Compositions containing alpha-2-adrenergic agonist components
Jul, 2021

(2 years ago)

US6627210 ABBVIE Compositions containing α-2-adrenergic agonist components
Jul, 2021

(2 years ago)

US6673337 ABBVIE Compositions containing alpha-2-adrenergic agonist components
Jul, 2021

(2 years ago)

US6641834 ABBVIE Compositions containing alpha-2-adrenergic agonist components
Jul, 2021

(2 years ago)

US9687443

(Pediatric)

ABBVIE Compositions containing alpha-2-adrenergic agonist components
Jan, 2022

(2 years ago)

US6562873

(Pediatric)

ABBVIE Compositions containing therapeutically active components having enhanced solubility
Jan, 2022

(2 years ago)

US9295641

(Pediatric)

ABBVIE Compositions containing alpha-2-adrenergic agonist components
Jan, 2022

(2 years ago)

US6627210

(Pediatric)

ABBVIE Compositions containing α-2-adrenergic agonist components
Jan, 2022

(2 years ago)

US6673337

(Pediatric)

ABBVIE Compositions containing alpha-2-adrenergic agonist components
Jan, 2022

(2 years ago)

US6641834

(Pediatric)

ABBVIE Compositions containing alpha-2-adrenergic agonist components
Jan, 2022

(2 years ago)

US8858961 ABBVIE Compositions containing alpha-2-adrenergic agonist components
Sep, 2023

(9 months ago)

US8858961

(Pediatric)

ABBVIE Compositions containing alpha-2-adrenergic agonist components
Mar, 2024

(3 months ago)

Market Authorisation Date: 19 August, 2005

Treatment: Reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension

Dosage: SOLUTION/DROPS;OPHTHALMIC

How can I launch a generic of ALPHAGAN P before it's drug patent expiration?
More Information on Dosage

ALPHAGAN P family patents

Family Patents

2. Lumify patents expiration

LUMIFY IPR and PTAB Proceedings
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11833245 BAUSCH AND LOMB INC Vasoconstriction compositions and methods of use
Jul, 2029

(5 years from now)

US11596600 BAUSCH AND LOMB INC Vasoconstriction compositions and methods of use
Jul, 2029

(5 years from now)

US9259425 BAUSCH AND LOMB INC Compositions and methods for eye whitening
Jul, 2030

(6 years from now)

US8293742 BAUSCH AND LOMB INC Preferential vasoconstriction compositions and methods of use
Jul, 2030

(6 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Dec 22, 2020

Market Authorisation Date: 22 December, 2017

Treatment: Relieves redness of the eye due to minor eye irritations

Dosage: SOLUTION/DROPS;OPHTHALMIC

How can I launch a generic of LUMIFY before it's drug patent expiration?
More Information on Dosage

LUMIFY family patents

Family Patents

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

3. Mirvaso patents expiration

MIRVASO's oppositions filed in EPO
MIRVASO IPR and PTAB Proceedings
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8859551 GALDERMA LABS LP Compounds, formulations, and methods for treating or preventing inflammatory skin disorders
May, 2024

(21 days ago)

US8410102 GALDERMA LABS LP Methods and compositions for treating or preventing erythema
May, 2025

(11 months from now)

US8231885 GALDERMA LABS LP Compounds, formulations, and methods for ameliorating telangiectasis
May, 2025

(11 months from now)

US8426410 GALDERMA LABS LP Compounds, formulations, and methods for treating or preventing inflammatory skin disorders
May, 2025

(11 months from now)

US7439241 GALDERMA LABS LP Compounds, formulations, and methods for treating or preventing rosacea
Aug, 2025

(1 year, 2 months from now)

US8513247 GALDERMA LABS LP Methods and compositions for safe and effective treatment of erythema
Mar, 2031

(6 years from now)

US8513249 GALDERMA LABS LP Methods and compositions for safe and effective treatment of erythema
Mar, 2031

(6 years from now)

US9861631 GALDERMA LABS LP Methods and compositions for safe and effective treatment of erythema
Mar, 2031

(6 years from now)

US9861632 GALDERMA LABS LP Methods and compositions for safe and effective treatment of erythema
Mar, 2031

(6 years from now)

US8163725 GALDERMA LABS LP Gel compositions and methods of use
Jun, 2031

(6 years from now)

US10201517 GALDERMA LABS LP Brimonidine gel compositions and methods of use
Jun, 2031

(6 years from now)

US8053427 GALDERMA LABS LP Brimonidine gel composition
Jun, 2031

(6 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Dosage Form(NDF) Aug 23, 2016

Market Authorisation Date: 23 August, 2013

Treatment: Topical treatment of facial erythema of rosacea

Dosage: GEL;TOPICAL

How can I launch a generic of MIRVASO before it's drug patent expiration?
More Information on Dosage

MIRVASO family patents

Family Patents

4. Qoliana patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7265117 SANDOZ Topical brimonidine tartrate formulations that lack chlorine dioxide
Aug, 2025

(1 year, 2 months from now)

Market Authorisation Date: 22 May, 2006

Treatment: NA

Dosage: SOLUTION/DROPS;OPHTHALMIC

More Information on Dosage

QOLIANA family patents

Family Patents